abs358.txt	background		there	are	multiple	known	individual-	and	practice-level	barriers	toenrollment	of	older	patients	with	cancer	to	clinical	trials		but	little	is	knownabout	how	the	clinical	research	workforce	feels	about	potential	higher-levelstrategy	changes	aimed	to	promote	increased	enrollment	of	older	patients	subjects		materials		and	methods		we	invited	all	11	351	alliance	for	clinicaltrials	in	oncology	(	alliance	)	members	to	participate	in	an	anonymous		web-basedsurvey	to	examine	awareness	of	current	accrual	patterns	for	older	patients	toclinical	trials		to	ascertain	consensus	on	how	to	tackle	enrollment	challenges	and	to	provide	the	impetus	for	high-level	changes	to	improve	clinical	trialaccrual	of	older	patients	with	cancer	results		during	the	period	from	february	28		2017		to	june	16		2017		1	146alliance	members	participated	(response	rate	=	10%)		including	a	national	diversesample	of	physicians		nurses		administrative/clinical	research	staff		and	patientadvocates	with	representation	from	community		academic		and	rural	sites		overall	one	third	felt	that	>50%	of	clinical	trial	enrollees	should	be	age	≥65		and	64	9%felt	the	alliance	could	improve	upon	enrollment	of	older	patients		the	four	mostcommonly	ranked	strategies	to	improve	enrollment	of	older	patients	were	creatingmore	dedicated	trials	for	this	population	(36	3%)		minimizing	exclusion	criteriafocused	on	comorbidity	(35	5%)		developing	independent	strategies	for	those	aged≥65	and	for	those	aged	≥70	(33	2%)		and	requiring	that	most/all	alliance	trialshave	a	specific	expansion	cohort	of	older	patients	(30	0%)	conclusion		we	anticipate	that	the	recommendations	from	>1	000	alliance	memberswill	continue	to	propel	important	strategy	changes	aimed	to	improve	accrual	ofolder	patients	with	cancer	to	clinical	trials	implications	for	practice		this	survey	of	the	alliance	for	clinical	trialsmembership	sought	opinions	on	potential		large-scale		national	strategies	toimprove	accrual	of	older	adults	with	cancer		consensus	was	found	around	multiplestrategies		including	creating	more	dedicated	trials	for	older	patients	developing	less	stringent	eligibility	criteria		and	mandating	expansion	cohortsof	older	patients	within	broader	alliance	trials		it	is	anticipated	that	therecommendations	from	>1	000	alliance	members	will	continue	to	propel	importantstrategy	changes	aimed	to	improve	accrual	of	older	patients	with	cancer	toclinical	trials	
